BMS's Empliciti meets in Phase II for MM

Bristol-Myers Squibb Co. (NYSE:BMY) reported data from the Phase II ELOQUENT-3 trial in 117 patients with relapsed or refractory multiple myeloma showing that Empliciti elotuzumab plus pomalidomide and low-dose dexamethasone met the primary endpoint of improving median progression-free survival (PFS) vs. pomalidomide and dexamethasone alone (10.3 vs. 4.7 months, p=0.0078). Data were presented at the European Hematology Association meeting in Stockholm.

On secondary endpoints, the triple combination led to an overall response rate (ORR) of 54% vs. 26% for pomalidomide and dexamethasone alone. Median duration of response was not reached. While overall survival (OS) data are not yet mature, they show a positive trend favoring the triple combination (HR=0.62)...